Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (R21/R33 Clinical Trial Not Allowed) | RFA DA 21 004

Frequently Asked Questions (FAQs): NIH RFA-DA-21-004

What is the focus of NIH funding opportunity RFA-DA-21-004?

This opportunity supports research on how biomolecular condensates (BMCs) and the molecules that regulate them influence HIV or SIV infection and disease in the context of substance use disorders. The emphasis is on linking condensate biology (including membrane-less, phase separation-driven cellular compartments) to HIV questions that matter for prevention and treatment, while accounting for effects of exposure to addictive substances.

What are biomolecular condensates (BMCs) in the context of this announcement?

BMCs are membrane-less cellular compartments that can form through processes such as phase separation. They can organize proteins and nucleic acids in ways that strongly shape gene expression, chromatin behavior, stress responses, and antiviral defense. The announcement is interested in how these structures and their regulators may affect HIV/SIV biology and disease outcomes, especially under substance exposure conditions.

Which viruses and disease contexts are included?

The scope includes HIV or SIV infection and disease. The research focus is on HIV/SIV replication, persistence, and mechanisms of disease, particularly where BMCs may play a direct or indirect role and where substance use disorders introduce additional biological or clinical complexity.

What parts of the HIV/SIV life cycle are considered relevant to this funding opportunity?

The scientific scope is broad but centered on replication, persistence, and disease mechanisms. Examples explicitly highlighted include HIV entry and early infection events, replication steps including viral gene expression, and mechanisms contributing to the establishment or maintenance of HIV latency.

Does this opportunity support HIV latency and persistence research?

Yes. The announcement specifically calls out the establishment and maintenance of HIV latency and encourages studies of how condensates may influence chromatin structure and transcriptional regulation around the provirus. This is framed as directly relevant to why HIV persists despite effective antiretroviral therapy.

How does chromatin and transcriptional regulation fit into the topic?

Latency-related work can include investigating how condensates influence chromatin structure and transcriptional regulation around the provirus. Because BMCs can shape gene expression and chromatin behavior, the opportunity encourages connecting these mechanisms to HIV persistence and control.

Is HIV pathogenesis, including neurologic outcomes, within scope?

Yes. The opportunity highlights HIV pathogenesis and specifically mentions neurodegenerative processes, signaling interest in how condensate biology might shape HIV-associated neurologic injury or other tissue-level disease outcomes.

What is meant by studying the "host side" of HIV infection in this announcement?

Applicants are invited to examine how BMCs or their regulators alter host cell functions in settings relevant to HIV infection and treatment. This includes understanding how host cellular pathways, immune signaling, inflammation, stress responses, and neuronal health might be influenced by condensates in ways that affect HIV replication, latency, or disease.

How are substance use disorders integrated into the research goals?

The announcement emphasizes accounting for the complications introduced by exposure to addictive substances. It encourages mechanistic studies of how drugs of abuse could reprogram cellular pathways and, in turn, alter condensate formation, composition, or function, affecting outcomes such as viral transcription, immune signaling, inflammation, neuronal health, replication, latency, or pathogenesis.

What types of condensates or phase-separated assemblies are mentioned as examples?

Examples include stress granules, nuclear bodies, transcriptional condensates, and other phase-separated assemblies. The opportunity frames these as possible structures whose behavior could be changed by substance exposure and thereby influence HIV-relevant cellular and viral processes.

Does the funding opportunity encourage descriptive or mechanistic research?

The framing is intended to push beyond purely descriptive work and toward mechanistic understanding. In practice, that means studies should aim to explain how and why substance exposure and condensate biology change cellular organization and how those changes influence HIV replication, latency, or disease mechanisms.

What is the grant mechanism for this opportunity?

The mechanism is an R21/R33. This generally supports a staged approach where early, exploratory work (R21) can transition to a more advanced, developmental phase (R33) if predefined milestones are met. It is positioned as a good fit for projects needing initial feasibility or proof-of-concept results before expanding into deeper mechanistic studies.

What does it mean that the opportunity is "Clinical Trial Not Allowed"?

It means the funded research cannot include clinical trial activities. The opportunity is intended for non-trial research such as basic, translational, or preclinical studies, and other human or animal research that does not meet the definition of a clinical trial.

Can applicants include human or animal research?

Yes, as described in the listing, the intent is to support non-trial research, which can include basic, translational, or preclinical studies and other human or animal research, as long as it does not meet the definition of a clinical trial.

What is the CFDA number associated with this opportunity?

The opportunity is associated with CFDA 93.279.

What is the activity category for this grant opportunity?

The listing describes it as being in the health and education activity category.

When was this funding opportunity created and when did it close?

The opportunity was created on 2020-02-24. The original closing date listed is 2020-07-20.

Is the award ceiling or expected number of awards provided in the listing?

No. The source listing does not provide an award ceiling or the expected number of awards. The listing notes that applicants would typically refer to the full announcement and NIH budget guidance for typical costs and project period expectations under the R21/R33 structure.

Who is eligible to apply?

Eligibility is broad and includes state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.

Are institutions serving specific populations explicitly included as eligible?

Yes. The announcement calls out Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs) as eligible applicant categories.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly listed among additional eligible applicant categories.

Are federal agencies eligible to apply?

Yes. Eligible federal agencies are included among the additional eligible applicant categories.

Can non-U.S. (foreign) entities apply?

Yes. Non-U.S. (foreign) entities are listed as eligible.

Are U.S. territories or possessions eligible to apply?

Yes. U.S. territories or possessions are explicitly listed as eligible.

What kinds of research outcomes is NIH aiming to enable through this opportunity?

The expected impact is to build a clearer, mechanistic picture of how condensate biology intersects with HIV replication and persistence, and how substance use-related exposures may modify these cellular systems in ways that influence outcomes. The listing also points to potential relevance for HIV cure efforts (through latency and gene regulation studies), improved control of viral replication, and mitigation of HIV-related pathogenesis, particularly in populations and contexts affected by substance use disorders.